$AUPH
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Healthcare
Sector
Biotechnology
Industry
Peter S. Greenleaf
CEO
130
Employees
$14.47
Current Price
$1.88B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 1 | 6 | $12,688,805.89 | 900,000 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 1 | 6 | $12,688,805.89 | 900,000 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 3 months | Buys | 1 | 6 | $12,688,805.89 | 900,000 | All Buys |
| Sells | 0 | 0 | - | - | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Feb 27, 2026 | TANG KEVIN Director | Purchase | 300,000 | $13.90 | $4,170,000.00 | View Details |
| Feb 27, 2026 | TANG KEVIN Director | Purchase | 214,839 | $14.12 | $3,033,526.68 | View Details |
| Feb 27, 2026 | TANG KEVIN Director | Purchase | 1,600 | $14.38 | $23,008.00 | View Details |
| Mar 2, 2026 | TANG KEVIN Director | Purchase | 83,561 | $14.33 | $1,197,429.13 | View Details |
| Mar 2, 2026 | TANG KEVIN Director | Purchase | 115,792 | $14.21 | $1,645,404.32 | View Details |
| Mar 3, 2026 | TANG KEVIN Director | Purchase | 184,208 | $14.22 | $2,619,437.76 | View Details |
4 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
Estimated$0.21
ActualN/A
Revenue
EstimatedN/A
ActualN/A